{"id":544100,"date":"2021-05-20T22:10:01","date_gmt":"2021-05-20T22:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544100"},"modified":"2021-05-20T22:10:01","modified_gmt":"2021-05-20T22:10:01","slug":"myocardial-infarction-mi-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myocardial-infarction-mi-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544100.html","title":{"rendered":"Myocardial Infarction (MI) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Myocardial<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Myocardial Infarction – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Myocardial Infarction (MI) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s<\/span> “Myocardial Infarction (MI) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/span>” report delivers an in-depth understanding of the Myocardial Infarction (MI), historical and forecasted epidemiology as well as the  Myocardial Infarction (MI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    Since <\/span>1987<\/span>, the incidence rate of hospitalization for acute myocardial infarction in the United States has declined by 4 to 5% per year. Nevertheless, approximately <\/span>550,000<\/span> first episodes and <\/span>200,000<\/span> recurrent episodes occur annually.<\/span><\/p>\n<\/li>\n

  2. \n

    As per the literature review, the global burden of acute myocardial infarction has shifted to low- and middle-income countries, an inverse relationship with income is clearly observable for the incidence of acute myocardial infarction as <\/span>1.92, 2.21,<\/span> and <\/span>4.13<\/span> cases per <\/span>1000<\/span> person-years in high-, middle-, and low-income countries respectively. Mitigation of the high burden of risk factors in higher-income countries was attributed to more use of preventive measures and revascularization procedures.<\/span><\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Myocardial Infarction (MI) market report covers a descriptive overview and comprehensive insight of the Myocardial Infarction (MI) epidemiology and Myocardial Infarction (MI) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

    2. The Myocardial Infarction (MI) market report provides insights on the current and emerging therapies.<\/span><\/p>\n

    3. Myocardial Infarction (MI) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/span><\/p>\n

    4. The Myocardial Infarction (MI) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myocardial Infarction (MI) market.<\/span><\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/myocardial-infarction-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Myocardial Infarction (MI): Overview<\/strong><\/p>\n

    A <\/span>myocardial infarction<\/span> (<\/span>MI<\/span>), commonly known as a heart attack, occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck or jaw.<\/span><\/p>\n

    The key players involved in the Myocardial Infarction (MI) market<\/a>:<\/strong><\/p>\n

      \n
    1. \n

      CSL Behring <\/span><\/p>\n<\/li>\n

    2. \n

      Recardio<\/span><\/p>\n<\/li>\n

    3. \n

      AstraZeneca <\/span><\/p>\n<\/li>\n

    4. \n

      Idorsia Pharmaceuticals<\/span><\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Myocardial Infarction (MI) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        CSL 112 <\/span><\/p>\n<\/li>\n

      2. \n

        Dutogliptin<\/span><\/p>\n<\/li>\n

      3. \n

        Farxiga<\/span><\/p>\n<\/li>\n

      4. \n

        ACT-246475<\/span><\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/myocardial-infarction-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/span><\/p>\n

        2. Executive Summary<\/span><\/p>\n

        3. SWOT analysis<\/span><\/p>\n

        4. Myocardial Infarction (MI) Patient Share (%) Overview at a Glance<\/span><\/p>\n

        5. Myocardial Infarction (MI) Market Overview at a Glance<\/span><\/p>\n

        6. Myocardial Infarction (MI) Disease Background and Overview<\/span><\/p>\n

        7. Myocardial Infarction (MI) Epidemiology and Patient Population<\/span><\/p>\n

        8. Country-Specific Patient Population of Myocardial Infarction (MI)<\/span><\/p>\n

        9. Myocardial Infarction (MI) Current Treatment and Medical Practices<\/span><\/p>\n

        10. Unmet Needs<\/span><\/p>\n

        11. Myocardial Infarction (MI) Emerging Therapies<\/span><\/p>\n

        12. Myocardial Infarction (MI) Market Outlook<\/span><\/p>\n

        13. Country-Wise Myocardial Infarction (MI) Market Analysis (2017–2030)<\/span><\/p>\n

        14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

        15. Market drivers<\/span><\/p>\n

        16. Market barriers<\/span><\/p>\n

        17. Appendix<\/span><\/p>\n

        18. Myocardial Infarction (MI) Report Methodology<\/span><\/p>\n

        19. DelveInsight Capabilities<\/span><\/p>\n

        20. Disclaimer<\/span><\/p>\n

        21. About DelveInsight<\/span><\/p>\n

        Related Reports:<\/strong><\/p>\n

        Myocardial Infarction (MI) – Pipeline Insights, 2021<\/strong><\/p>\n

        “<\/span>Myocardial Infarction (MI) Pipeline Insight, 2021<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myocardial Infarction (MI) market. A detailed picture of the Myocardial Infarction (MI) pipeline landscape is provided, which includes the disease overview and  Myocardial Infarction (MI) treatment guidelines.<\/span><\/p>\n

        Myocardial Infarction (MI) – Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s <\/span>‘Myocardial Infarction (MI)- Epidemiology Forecast to 2030’ <\/span>report delivers an in-depth understanding of the disease, historical and forecasted Myocardial Infarction (MI) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight’s “Myocardial Infarction – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544100","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544100"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544100\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}